Genoil (GNOLF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2024, filed May 1, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GNOLF SEC filings page.
Genoil Inc (GNOLF) reported $0 in revenue for fiscal year 2024. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
Reported operations consume cash, while financing inflows have funded activity and liabilities now exceed total assets.
In FY2024, operating cash flow was-$606K while financing cash flow was$608K , showing that reported cash needs were roughly offset through financing rather than operating receipts. The same pattern appeared in FY2023, when operating cash flow of-$646K was nearly matched by financing cash flow of$651K , indicating a recurring funding structure.
By FY2024, liabilities of
From FY2023 to FY2024, assets fell
Financial Health Signals
We do not publish a peer-relative financial health score for Genoil Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Genoil Inc passes 0 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
Key Financial Metrics
Earnings & Revenue
Genoil Inc generated $0 in revenue in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Genoil Inc held $12K in cash against $214K in long-term debt as of fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
None of these metrics is reported for fiscal year 2024.
Capital Allocation
None of these metrics is reported for fiscal year 2024.
GNOLF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
GNOLF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F |
|---|---|---|---|---|---|
| Total Assets | $134K-44.5% | $241K+55.6% | $155K-7.7% | $168K-15.9% | $199K |
| Current Assets | $96K+1.3% | $95K-14.6% | $112K-10.3% | $124K-20.3% | $156K |
| Cash & Equivalents | $12K+15.0% | $10K+107.5% | $5K+41933.3% | $12-99.6% | $3K |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Total Liabilities | $458K+21.9% | $376K-96.6% | $11.1M+21.0% | $9.2M+17.6% | $7.8M |
| Current Liabilities | $244K+45.5% | $168K-98.5% | $11.1M+21.0% | $9.2M+196.4% | $3.1M |
| Non-Current Liabilities | $214K+3.0% | $208Kn/m | $0n/m | $0-100.0% | $4.7M |
| Long-Term Debt | $214K+3.0% | $208Kn/m | $0n/m | $0-100.0% | $4.7M |
| Total Equity | -$325Kn/m | -$135Kn/m | -$11.0Mn/m | -$9.0Mn/m | -$7.6M |
| Retained Earnings | -$105.9Mn/m | -$103.8Mn/m | -$99.5Mn/m | -$95.9Mn/m | -$93.3M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
GNOLF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Share Buybacks.
GNOLF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$325K), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.40), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Genoil Inc GNOLF | FY2024 | $0 | N/A | N/A | $49.2M | — |
| Koil Energy Solutions Inc KLNG | FY2025 | $24.1M | -$38K | -0.2% | $34.6M | — |
| NXT Energy Sltns Inc NSFDF | FY2024 | $447K | -$6.3M | N/A | $33.5M | — |
| QS Energy Inc QSEP | FY2025 | $0 | N/A | N/A | $33.9M | — |
Where Genoil Inc Ranks
Frequently Asked Questions
Genoil Inc (GNOLF) reported $0 in total revenue for fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
As of fiscal year 2024, Genoil Inc (GNOLF) had $12K in cash and equivalents against $214K in long-term debt.
Genoil Inc (GNOLF) recorded an outflow of $606K in operating cash flow during fiscal year 2024, representing cash used by core business activities.
Genoil Inc (GNOLF) had $134K in total assets as of fiscal year 2024, including both current and long-term assets.
Genoil Inc (GNOLF) had a current ratio of 0.40 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Genoil Inc (GNOLF) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $49.2M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Genoil Inc (GNOLF) has no price-to-sales ratio at the moment: revenue is not positive (FY2024). The market capitalization is $49.2M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2024, Genoil Inc (GNOLF) held $12K in cash, cash equivalents and investments, and reported an operating cash outflow of $606K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Genoil Inc (GNOLF) has negative shareholder equity of -$325K as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Genoil Inc (GNOLF) has a Piotroski F-Score of 0 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.